æ¥çµã¡ãã£ã«ã«éå¶ã®ãæ¥æ¬æ大ç´ãå»å¸«æ±äººã¡ãã£ã¢ã転è·æ¯æ´ä¼ç¤¾ãæ±ãæ±äººæ å ±ã®ã»ããå»çæ©é¢ããã®ç´æ¥æ±äººæ å ±ãæ²è¼ï¼
12æ8 æ¡å¼µæè¡å§ã®ä¸ãéãã«è¦é ã«ãã´ãª:æ¬æ æ§é«è¡å§ æ¡å¼µæè¡å§ã®ä¸ãéãã«è¦é https://medical-tribune.co.jp/rensai/2016/1207505848/ åéç 究æç é¢ç³å°¿ç ã»ã³ã¿ã¼ã»å±±ç°æã»ã³ã¿ã¼é·ã«ãããæ¡å¼µæè¡å§ãã«ã¤ãã¦ã®è§£èª¬ã§ãã ç³å°¿ç å°éå»ã¯ãè¡å§ãã«ã¤ãã¦ã©ã®ããã«èªãããã®ã§ããããã ç 究ã®èæ¯ï¼è¡å§ã«é¢ãã大ããªç 究ææãæ¨å¹´ãä»å¹´ã¨å ±å æè¿ãé«è¡å§ã«é¢ããèãæ¹ã大ããæºãã¦ããã ACCORD-BP試é¨ã§ã¯ãç³å°¿ç æ£è ã対象ã«å縮æè¡å§ï¼SBPï¼120mmHgæªæºãç®æããä»å ¥ãè¡ããå¿è¡ç®¡ã¤ãã³ãã«å¤§ããªå·®ç°ãçããªãã£ãã ãã®ãã¨ã¯ãããã¾ã§ã®"The lower, the better"ã®èãæ¹ãæºãããã2014å¹´ã¾ã§130/80mmHgæªæºãç³å°¿ç æ£è ã®éå§ç®æ¨ã¨ãã¦ããç±³å½ç³å°¿ç å¦ä¼ããã¦ã2015年以é
10æ1 ãFFR-CTã å®å®çå¿çã®è¨ºçãFFR-CTã§å¤ãã å¿ã«ãã»ã·ã³ãä¸è¦ï¼CTã ãã§PCIã®å¤æå¯è½ã« http://medical.nikkeibp.co.jp/leaf/mem/pub/report/201609/548070.html å åèç¾æ£ã®é侵襲çæ¤æ»ã¨ãã¦æ®åããå åèCTã§ãå¿çèè¡ã®è©ä¾¡ãã§ããããã«ãªã£ãã å®å®çå¿çã®è¨ºçã§ã¯è¿å¹´ãççªã®è¦è¦çè©ä¾¡ã«é ¼ã£ãçµç®çå åèã¤ã³ã¿ã¼ãã³ã·ã§ã³æ²»çï¼PCIï¼ã®éå°é©ç¨ãææããã¦ããã FFR-CTã¨å¼ã°ããæ¬æ¤æ»ã®å°å ¥ã§ãå¿èã«ãã¼ãã«æ¤æ»ãè² è·å¿çè¡æµã·ã³ãã°ã©ãã£ã¼ãè¡ããã¨ããèè¡ã®æ å ±ãå å³ããããé©åãªPCIæ½è¡ã®å¤æãå¯è½ã«ãªãã PCIã«åãçµã循ç°å¨å»ã®éã§ãå åèççªã«ããå¿çèè¡ã®ç¨åº¦ãé侵襲çã«è©ä¾¡ãããFFR-CTãã¨ããæ¤æ»ã話é¡ã¨ãªã£ã¦ããã æ®åããå åèCTã®ãã¼ã¿ã使ããççª
2æ16 å¿æ¿ç´°åã¯å¥³æ§ã®æ¹ãå±éº å¿æ¿ç´°åã¯å¥³æ§ã®æ¹ãå¼·åãªå±éºå åã«ãªã  å¿è¡ç®¡æ»äº¡ãè³åä¸ã®ãªã¹ã¯ãç·æ§ãããå¢å http://medical.nikkeibp.co.jp/leaf/mem/pub/hotnews/bmj/201602/545585.html ç·æ§ããã女æ§ã®æ¹ããå¿æ¿ç´°åï¼AFï¼ã¯å¿è¡ç®¡ç¾æ£ãæ»äº¡ã®å¼·åãªå±éºå åã§ãããã¨ãæããã«ãªã£ãã AFã¨å¿è¡ç®¡ç¾æ£ãæ»äº¡ã¨ã®é¢ä¿ã®å¼·ãã«æ§å·®ããããã©ãããæ¤è¨ããããã«ãã³ãã¼ãç 究ã対象ã¨ããã¡ã¿ã¢ããªã·ã¹ãè±å½ã®ç 究è ãè¡ã£ãçµæãBMJèªé»åçã«å ±åããããï¼2016.1.19ï¼ èè ãã¯ãMedlineã¨Embaseã«1966å¹´1æãã2015å¹´3æã¾ã§ã«çºè¡¨ãããç 究ã対象ã«ç³»çµ±çã¬ãã¥ã¼ãå®æ½ã çµã¿å ¥ãã®æ¡ä»¶ã¯ãæä½ã§ã50人以ä¸ã®AFæ£è ã¨AFã§ã¯ãªã人ã ãç»é²ãã¦ããã追跡æéã®ä¸å¤®å¤ã6ãæ以ä¸ã®
11æ6 å©å°¿è¬ã¯å ¨ã¦ãåããï¼ ã«ãã´ãª:éå§å¤ å©å°¿è¬ã¯å ¨ã¦ãåããï¼ãæ¥æ¬é«è¡å§å¦ä¼ã§ï¼æ°ããã£ãã¼ã https://medical-tribune.co.jp/news/2015/1104037711/ ï¼MT2015.11.4ï¼ å©å°¿è¬ã¯ç©æ¥µçé©å¿ããªãå ´åï¼é«è¡å§æ²»çã®ç¬¬ä¸é¸æè¬ã«ä½ç½®ä»ãããã¦ãããã®ã®ï¼åå¤ããã¯ãããé åå¤ã¨ãã¦ã®ä½¿ç¨ã®æ¹ãé »åº¦ã¯é«ãã ããå½ã§ä½¿ç¨ã§ããéå§å©å°¿è¬ã¯éããããï¼ã»ã¼åä¸ã¨ãã¦åãæ±ããã¦ããï¼ç±³å½ã®ããã«æ¯è¼ããããã¨ã¯ã»ã¨ãã©ãªãã ãéå§å©å°¿è¬ã¯ãã¹ã¦ä¸ç·ãï¼ãã®ãã¼ãã§è¡ããã第38åæ¥æ¬é«è¡å§å¦ä¼ç·ä¼ï¼2015.10.ï¼ï½11ï¼ã®ãã£ãã¼ãã§ã¯ï¼å©å°¿è¬ã¯ãåãã§ãªãããåããã®ä¸¡é¢ããï¼å°é家ï¼æ°ãè°è«ããã ãåãã§ãªããç«å ´ãã   åªå£ã§ã¯ãªãéããèæ ®ãã対å¿ã è¿ç¿å¤§å¦å ç§å¦è¬åº§è èå ç§ä¸»ä»»ææã®æ馬ç§äºæ°ã¯ï¼æ¬§ç±³ã§ã¯
10æ25 NOACå¦æ¹ã®å®é â¡ ã«ãã´ãª:NOAC NOACå¦æ¹ã®å®éã¯ãããã  ⡠è¬ç©ç¸äºä½ç¨ï¼ç¹ã«æã¦ãããè¬ã¨ã®ä½µç¨ã«æ³¨æã http://mtpro.medical-tribune.co.jp/mtpronews/1410/1410051.html â è³åä¸ã§æååºçæ³ãè¡ã£ã¦ããå ´åã«æ³¨æããªããã°ãªããªãã®ã¯æã¦ãããè¬ï¼anti-epileptic drugï¼AEDï¼ã¨ã®ä½µç¨ã«ããè¬ç©ç¸äºä½ç¨ã§ããã â ã¯ã«ãã¡ãªã³å æä¸ã«å¿åæ§è³å¡æ çãçåæ§ã¦ããããä½µçºãï¼ã«ã«ããã¼ãã³ãä½µç¨ããé端ï¼ã¯ã«ãã¡ãªã³ãå¹ããªããªããã¨ãããã ã¯ã«ãã¡ãªã³ã¨å¾æ¥ã®æã¦ãããè¬ã¨ã®âç¸æ§ã®æªãâã¯ããç¥ããã¦ããã â NOACã¯ï¼è¬å¤ã®ç¹å¾´ï¼ç¦å¿ï¼æ éæä¸ï¼è¬ç©ç¸äºä½ç¨ï¼æ¸éåºæºãçç¥ããã¨ã¨ãã«ï¼è¬å¹ãã¢ãã¿ãªã³ã°ã§ããªãããã«æã¦ãããè¬ã¨ä½µç¨ããå ´åã®è¬ç©ç¸äºä½ç¨ã«æ³¨æãå¿ è¦
å種é«è¡å§GLã«ããã¦60ï½80æ³ã®éå§ç®æ¨ã¯140/90mmHgæªæºã¨è¨å®ããã¦ãã¾ãã ããã«å¯¾ãï¼æ¨å¹´ï¼2013å¹´ï¼12æçºè¡¨ãããJNC-8ã¯ï¼60æ³ä»¥ä¸ã®ä¸è¬äººå£ã«ãããéå§ç®æ¨ã150/90mmHgæªæºã¨ä¸é¨ç·©åãã¾ããã ãããï¼ãã®å¦¥å½æ§ã«ã¤ãã¦å¤§ããªæ³¢ç´ãåºãã£ã¦ãã¾ããã å®ã¯JNC-8ã®è©ä¾¡å¯¾è±¡ã«ã¯ãCADã®ããé«é½¢é«è¡å§æ£è ã¯å«ã¾ãã¦ãã¾ããã ãããã£ã対象ãå«ãã INVEST試é¨ã®post hoc解æçµæãæè¿ã«ãªã£ã¦JACCèªã«çºè¡¨ããã¾ããã ããã§ã¯ãJNC-8ãå§åãã60æ³ä»¥ä¸ã®ç®æ¨å¤ãç®æãæ²»çã¯å¿è¡ç®¡ãããã£ããã®é¢ã§è³é©ã§ã¯ãªãã¨ã®è¦è§£ã示ããã¾ããã JNC-8ã®ã60æ³ä»¥ä¸ã®éå§ç®æ¨ã¯150mmHgæªæºãã«åèæ±ããçµæï¼ INVEST試é¨ã®post hoc解æ http://mtpro.medical-tribune.co.jp/mtpro
ãã¤ã³ã ãªã¡ã¬ï¼èèªé ¸ã«ã¯å¿èä¿è·ä½ç¨ããããã¨ãç¥ããã¦ããã ãã¯ããã¡ã¼ã¸ããªã¡ã¬ï¼èèªé ¸ããçæãã代è¬ç©ï¼ï¼ï¼ï¼¨ï¼¥ï¼°ï¼¥ã«ãããå¿èã®ççãç·ç¶åãæå¶ãããå¿æ©è½ãæ¹åããã ï¼ï¼ï¼ï¼¨ï¼¥ï¼°ï¼¥ãèµ·ç¹ã¨ããå¿ä¸å ¨ã«å¯¾ããæ°ããªå¿æ©è½æ¹åè¬ã¸ã®å±éãæå¾ ãããã JST æ¦ç¥çåµé ç 究æ¨é²äºæ¥ã«ããã¦ãçåå¦ç 究æ çµ±åçå½å»ç§å¦ç 究ã»ã³ã¿ã¼ï¼ï¼²ï¼©ï¼«ï¼¥ï¼®ï¼ï¼©ï¼ï¼³ï¼ã®æç° èª ããã¼ã ãªã¼ãã¼ï¼å ãæ±äº¬å¤§å¦ 大å¦é¢è¬å¦ç³»ç 究ç§ãåææï¼ãã¯ããªã¡ã¬ï¼èèªé ¸æ³¨ï¼ï¼ã®å¿èä¿è·ä½ç¨ã«é¢ãã代è¬ç£ç©ï¼ï¼ï¼ï¼¨ï¼¥ï¼°ï¼¥ãåå®ãããã®ä»£è¬ç£ç©ãå¿ä¸å ¨ã¢ãã«ãã¦ã¹ã«æä¸ããé¡èãªäºé²ã»æ²»çå¹æãè¦ãã ãã¾ããã éæ²¹ã«å¤ãå«ã¾ããã¨ã¤ã³ãµãã³ã¿ã¨ã³é ¸ï¼ï¼¥ï¼°ï¼¡ï¼ããã³ãµãããµã¨ã³é ¸ï¼ï¼¤ï¼¨ï¼¡ï¼ãªã©ã®ãªã¡ã¬ï¼èèªé ¸ã¯ãããå«ãåºä¹³é¡ã¯ä½å ã§çæã§ãã¾ããããé£ã¹ç©ããæåãããã¨ã§å¿èãä¿è·ããä½ç¨ããããã¨ã
⺠2012 (1163) ⺠1æ (87) ⺠1æ 17 (2) ⺠1æ 18 (12) ⺠1æ 19 (9) ⺠1æ 20 (6) ⺠1æ 21 (3) ⺠1æ 22 (1) ⺠1æ 23 (5) ⺠1æ 24 (8) ⺠1æ 25 (6) ⺠1æ 26 (7) ⺠1æ 27 (7) ⺠1æ 28 (3) ⺠1æ 30 (6) ⺠1æ 31 (12) ⺠2æ (173) ⺠2æ 01 (7) ⺠2æ 02 (11) ⺠2æ 03 (8) ⺠2æ 04 (5) ⺠2æ 05 (2) ⺠2æ 06 (5) ⺠2æ 07 (4) ⺠2æ 08 (8) ⺠2æ 09 (6) ⺠2æ 10 (8) ⺠2æ 11 (3) ⺠2æ 12 (1) ⺠2æ 13 (7) ⺠2æ 14 (8) ⺠2æ 15 (7) ⺠2æ 16 (11) âº
â¼ 2012 (1163) ⺠1æ (87) ⺠1æ 17 (2) ⺠1æ 18 (12) ⺠1æ 19 (9) ⺠1æ 20 (6) ⺠1æ 21 (3) ⺠1æ 22 (1) ⺠1æ 23 (5) ⺠1æ 24 (8) ⺠1æ 25 (6) ⺠1æ 26 (7) ⺠1æ 27 (7) ⺠1æ 28 (3) ⺠1æ 30 (6) ⺠1æ 31 (12) ⺠2æ (173) ⺠2æ 01 (7) ⺠2æ 02 (11) ⺠2æ 03 (8) ⺠2æ 04 (5) ⺠2æ 05 (2) ⺠2æ 06 (5) ⺠2æ 07 (4) ⺠2æ 08 (8) ⺠2æ 09 (6) ⺠2æ 10 (8) ⺠2æ 11 (3) ⺠2æ 12 (1) ⺠2æ 13 (7) ⺠2æ 14 (8) ⺠2æ 15 (7) ⺠2æ 16 (11) âº
çºä½æ§å¿æ¿ç´°å第1é¸ææ²»çã«ããã¦ãã«ãã¼ãã«ç¼ç¼è¡ã¨æä¸æ´èè¬ã¯å¹æã«ããã¦åç 2å¹´éã«ããã¦ãç´¯ç©burdenã®ç¾¤éå·®ã¯è¦ããã ä¸æ´èburden 90ãã¼ã»ã³ã¿ã¤ã« 13%ã¨19% p=0.10 è¡é¢é£åä½µçã®å¯ä½ç¨ã¨ãé¤ç´°åå¿ è¦ã»å¿æ¿ç´°åçºççã«å·®ããããæ²»çé¸æã®è¦ã¨ãªãã¯ãã Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, et. al. N Engl J Med 2012; 367:1587-1595October 25, 2012DOI: 10.1056/NEJMoa1113566 çºä½æ§å¿æ¿ç´°åã»æä¸æ´èè¬ç©ä½¿ç¨æ´ç¡ãã®294åã®æ£è ãååæ²»çæ¦ç¥ã¨ã㦠ã»radiofrequency catheter ablation
â¼ 2012 (1163) ⺠1æ (87) ⺠1æ 17 (2) ⺠1æ 18 (12) ⺠1æ 19 (9) ⺠1æ 20 (6) ⺠1æ 21 (3) ⺠1æ 22 (1) ⺠1æ 23 (5) ⺠1æ 24 (8) ⺠1æ 25 (6) ⺠1æ 26 (7) ⺠1æ 27 (7) ⺠1æ 28 (3) ⺠1æ 30 (6) ⺠1æ 31 (12) ⺠2æ (173) ⺠2æ 01 (7) ⺠2æ 02 (11) ⺠2æ 03 (8) ⺠2æ 04 (5) ⺠2æ 05 (2) ⺠2æ 06 (5) ⺠2æ 07 (4) ⺠2æ 08 (8) ⺠2æ 09 (6) ⺠2æ 10 (8) ⺠2æ 11 (3) ⺠2æ 12 (1) ⺠2æ 13 (7) ⺠2æ 14 (8) ⺠2æ 15 (7) ⺠2æ 16 (11) âº
Uchino 㨠Hernandez ã«ããã2011å¹´3æã¾ã§ã®ãdabigatranã®æ¥æ§å ç¾æ£ã¢ã¦ãã«ã ï¼å¿çæ¢å¡ï¼MIï¼ã»æ¥æ§å çå群ï¼ACS)ã¢ã¦ãã«ã éå£æ§ã©ã³ãã åãã©ã¤ã¢ã«ã®ã·ã¹ãããã£ãã¯ã»ã¬ãã¥ã¼ãã¡ã¿ã¢ããªã·ã¹ å¿æ¿ç´°ååä¸äºé²2ç 究ãå«ã 7ãã©ã¤ã¢ã«ï¼n=30 514)ãæ¥æ§å åèè¡æ å¡æ ãï¼ãACSãï¼ãçææ·±é¨éèè¡æ çäºé² ãï¼ ã¯ã¼ãã¡ãªã³ãenoxaparinããã©ã·ã¼ãæ¯è¼ã®å¯¾ç §ç¾¤æ¯è¼ã§ãDabigatranã¯ãææã«MIãACSãªã¹ã¯å¢å ã¨é¢é£ dabigatranã 237/20 000 [1.19%]ã vs controlã83/10 514 [0.79%] ãªããºæ¯ (Mantel-Haenszel), 1.33; 95% CI 1.03-1.71; P = .03) è¨åºå»ã¯ãããã¬ãã©ã³ä½¿ç¨ã«ããå¿è¡ç®¡ç¾æ£ã¸ã®é大ãªæªå½±é¿ãèæ ®ã使ãã¹ã
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ã©ã³ãã³ã°
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}